Drug development firm Triphase Accelerator has received approval from Health Canada to begin its Phase I trial of marizomib in combination with bevacizumab (Avastin) to treat patients with recurrent malignant glioma in Canada.
Marizomib is a new potent proteasome inhibitor that readily penetrates the blood brain barrier, and also prevents the breakdown of proteins involved in signal transduction, which inhibits tumour growth.
Go deeper with GlobalData
The trial will be conducted at the University Health Network’s Princess Margaret Cancer Centre in Toronto, Canada, and will be led by Brain Tumour Centre medical director and principal investigator Warren Mason.
Dr Mason noted: “Malignant gliomas are rarely curable, and the prognosis for patients with high-grade gliomas is generally poor. One of the few treatment options currently available for recurrent gliomas is bevacizumab.
“As a result, new treatment options are urgently needed for patients suffering from this universally fatal disease.
“Published literature indicates that targeting the proteasome in glioma cells has shown significant anti-tumour activity. Given that marizomib is a first-in-class pan-proteasome inhibitor that is brain penetrant, I am looking forward to evaluating this combination regimen in my patients.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe multi-centre, open-label, dose-escalation trial is designed to determine the maximum tolerated dose of marizomib and bevacizumab in bevacizumab-naïve patients with WHO Grade IV malignant glioma who are in their first or second relapse.
The trial’s second stage will evaluate the safety and activity of the recommended dose for future Phase II studies.
Currently, the trial is underway in the US at The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, and at the Comprehensive Brain Tumor Program at the University of California, Irvine Medical Center.
Triphase Accelerator R&D head and chief scientific officer Mohit Trikha said: “We look forward to working closely with Dr Mason and his staff at the Princess Margaret Cancer Centre on this important study of marizomib in glioma.”
Marizomib is being developed by the company in both intravenous and oral formulations as a potential proteasome inhibitor for haematologic malignancies and solid tumours.
Source: Press Release
http://triphaseco.com/wp-content/uploads/2015/09/Triphase_GBM-PMH-study-initiation_news_release_092515_FINAL-002.pdf
Triphase Accelerator Corporation Announces Health Canada Approval to Initiate Marizomib Phase 1 Study in Recurrent Glioma Patients
Toronto and San Diego, September 25, 2015 — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal transduction, which inhibits tumor growth.
The study will be conducted in Canada at the University Health Network’s Princess Margaret Cancer Centre in Toronto. It will be led by principal investigator Warren Mason, M.D., Medical Director of the Brain Tumour Centre and Kirchmann Family Chair in Neuro-oncology Research at the Princess Margaret Cancer Centre.
“Malignant gliomas are rarely curable, and the prognosis for patients with high-grade gliomas is generally poor. One of the few treatment options currently available for recurrent gliomas is bevacizumab. As a result, new treatment options are urgently needed for patients suffering from this universally fatal disease,” said Dr. Mason. “Published literature indicates that targeting the proteasome in glioma cells has shown significant anti-tumor activity. Given that marizomib is a first-in-class pan-proteasome inhibitor that is brain penetrant, I am looking forward to evaluating this combination regimen in my patients.”
The multicenter, open-label, dose-escalation study is designed to determine the maximum tolerated dose of marizomib and bevacizumab in bevacizumab-naïve patients with WHO Grade IV malignant glioma who are in their first or second relapse. The second stage of the study will evaluate the safety and activity of the recommended dose for future Phase 2 studies. The study is currently underway in the United States at The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center and at the Comprehensive Brain Tumor Program at the University of California, Irvine Medical Center.
“We look forward to working closely with Dr. Mason and his staff at the Princess Margaret Cancer Centre on this important study of marizomib in glioma,” said Mohit Trikha, Ph.D., Chief Scientific Officer and Head of R&D at Triphase Accelerator.
About Marizomi
Marizomib is a novel and highly potent proteasome inhibitor that irreversibly binds and inhibits all three proteasome subunits, which translates into longer duration of effect and potentially improved clinical activity. Triphase Accelerator is developing marizomib in both intravenous and oral formulations as a potential best-in-class proteasome inhibitor for hematologic malignancies and solid tumors. The IV formulation has been evaluated in more than 270 patients in six clinical studies in patients with solid and hematologic malignancies, either as a single agent or in combination with dexamethasone, a histone deacetylase inhibitor, or an immunomodulatory drug.
In addition to the Phase 1 proof-of-concept clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with Grade IV malignant glioma (glioblastoma) being conducted in the United States and Canada, Triphase Accelerator is currently evaluating marizomib in a Phase 1 study in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Triphase Accelerator is also evaluating an oral formulation in preclinical studies. The Company has received Orphan Drug designation for marizomib in multiple myeloma in the United States and the European Union.
About Triphase Accelerator
Triphase Accelerator is a private drug development company with a primary focus on oncology and with operations in Toronto and San Diego. Triphase Accelerator is dedicated to advancing novel compounds through Phase 2 proof-of-concept clinical studies using a unique, science-based, high-quality model that is faster and more cost-effective than traditional pharmaceutical and biotech industry drug development approaches. Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS. It has a strategic relationship with Celgene for oncology-focused drug development opportunities. For more information, visit www.triphaseco.com or Linkedin.
